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Abstract Although some studies have described the
pharmacokinetics and pharmacodynamics of donepezil in
the peripheral compartment, studies focused on drug
transport across the blood–brain barrier are still very rare.
To our knowledge, the fluctuation in the cerebrospinal fluid
concentration of donepezil after administration of the drug
has not been described in the literature so far. We recruited
16 patients regularly taking a standard therapeutic dose of
donepezil (10 mg per day). All patients (Caucasian race)
were treated for at least three months with a stable dose of
10 mg per day prior to sample collection. Patients were
divided into two groups depending on the time of plasma
and cerebrospinal fluid sampling: 12 h (n = 9; 4 M/5F
aged 78.68 ± 7.35 years) and 24 h (n = 7; 3 M/4F aged
77.14 ± 5.87 years) after donepezil administration. The
cerebrospinal fluid sample was collected by standard
lumbar puncture technique using a single-use traumatic
needle. The samples were analysed on an Agilent 1260
Series liquid chromatograph comprising a degasser, a
quaternary pump, a light-tight autosampler unit set, a
thermostated column compartment, and a UV/VIS detec-
tor. Agilent ChemStation software, the statistical software
Prism4, version 5.0 (GraphPad Software, USA), and IBM
SPSS Statistics were used for the analysis of the results.
The difference in plasma concentration of donepezil after
12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h
(29.38 ± 1.71 ng/ml) was nonsignificant. In contrast, the
donepezil concentration in the cerebrospinal fluid was
significantly higher in the 24-h interval (7.54 ± 0.55 ng/
ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml,
which is *70 % based on mean cerebrospinal fluid val-
ues). Based on these data, it is plausible to predict that
donepezil might produce a stronger AChE inhibition in the
brain at 24 h compared with 12 h following the adminis-
tration. This information may help physicians individually
adjust the time of drug administration in the patients
according to time course of the disease symptoms.
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CV Coefficient of variation
ER Extended-release formulation
FDA Food and drug administration
HPLC High-performance liquid chromatography
IR Immediate-release formulation
P-gp P-glycoprotein
SEM Standard error of mean
SR Sustained-release formulation
t Elimination half-life
tmax,ss Time to reach Cmax,ss
UGT Uridine 50-diphosphoglucuronosyltransferase
Vd Apparent volume of distribution
Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder affecting a significant proportion of the
elderly population. With respect to continual increase of
life expectancy, AD is expected to affect more than 100
million individuals worldwide in the near future (Giacobini
2008). The aetiology of AD includes upstream and down-
stream processes in which cholinergic deficits are clinically
relevant. Cholinergic deficits have been shown to be caused
by degeneration of the subcortical regions, especially the
hippocampal projections to the basal forebrain. Hip-
pocampal cholinergic deficits are responsible for impaired
memory processing (Talesa 2001). Inhibition of the
enzyme acetylcholinesterase (AChE), which breaks down
acetylcholine at the synapse, may be one method of
increasing the concentration of this neurotransmitter in
certain areas of the brain and may affect the symptoms of
the disease. Some evidence suggests that the administration
of rivastigmine, donepezil, or galantamine may be benefi-
cial in patients with AD (Ritchie et al. 2004). The selective
AChE inhibitor donepezil is widely used as a symptomatic
treatment for the disease (Darreh-Shori et al. 2006).
Donepezil is well absorbed, with a bioavailability
approaching 100 %. Peak plasma concentrations (Cmax)
are achieved after 3–5 h in patients receiving immediate-
release (5- and 10-mg tablets) and 6 h in those receiving
sustained-release (23-mg tablet) formulations (see Table 1;
taken from Noetzli and Eap 2013). In the USA, the FDA-
approved dose is higher at 23 mg daily. Although some
studies have described the pharmacokinetics and pharma-
codynamics of the drug in the peripheral compartment,
studies focused on drug penetration across the blood–brain
barrier are still very rare. To our knowledge, the changes in
cerebrospinal fluid (CSF) concentrations between doses of
donepezil have not been described in the literature to date.
Materials and Methods
Sampling and Patients
Sixteen patients (Caucasian race) who regularly use a
standard therapeutic dose of donepezil (10 mg per day)
were recruited into the study. All patients were treated for
at least 3 months with a stable dose of 10 mg per day prior
to sample collection. The patients were randomly divided
into two groups depending on the time of plasma and CSF
sampling: 12 h (n = 9; 4 M/5F aged 78.68 ± 7.35 years)
and 24 h (n = 7; 3 M/4F aged 77.14 ± 5.87 years) fol-
lowing donepezil administration.
All patients signed an informed consent to lumbar punc-
ture, and the study was approved and supervised by the
Local Ethics Committee. The study was progressed
according to national and international guidelines (Ressner
et al. 2008; Hort et al. 2010); the lumbar puncture was part of
the standard diagnostic investigation (CSF tau and Ab42 can
be used as markers in patients suspected of having AD, but in
whom the clinical diagnosis is uncertain). The cerebrospinal
fluid sample was collected by a standard lumbar puncture
technique using a single-use traumatic needle for the purpose
of this research project. The diagnosis of probable AD was
made by the exclusion of other types of dementia in accor-
dance with the NINCDS-ADRDA criteria (National Institute
of Neurological and Communication Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association)
(McKhann et al. 1984; Hort et al. 2010). Dementia was
established by clinical and neuropsychological examination.
Cognitive impairment also had to be progressive and pre-
sented in two or more areas of cognition. The onset of the
deficit had to be recognised between 40 and 90 years of age,
and finally other diseases capable of demonstrating as
dementia syndrome had to be excluded.
Chemicals
Chemicals for sample preparation and high-performance
liquid chromatography (HPLC) measurement were pur-
chased from Sigma-Aldrich (Prague branch, Czech
Republic) and were of the best available quality: acetoni-
trile, gradient grade; LiChrosolv in analytical grade;
n-hexane and 1-butanol in gradient grade. All other
reagents used in analytical methods and sample preparation
were of analytical grade. The water used in the study was
double-distilled and was of deionised HPLC grade.
Neurotox Res (2017) 31:162–168 163
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Instrumentation
The samples were analysed on an Agilent 1260 Series
liquid chromatograph (Palo Alto, CA, USA) composed of a
degasser, a quaternary pump, a light-tight autosampler unit
set, a thermostated column compartment, and a UV/VIS
detector. Agilent ChemStation software (Palo Alto, CA,
USA) and the statistical software Prism4 (GraphPad Soft-
ware, USA) were used for data analysis.
Separation Conditions for Donepezil in Plasma
and CSF Samples
An analytical column (Waters Spherisorb S5 W/
250 mm 9 4.6 i.d.; 5 lm particle size/with guard column
(Waters Spherisorb S5 W/30 mm 9 4.6 mm i.d./) was
used for the analysis. The mobile phase contained ace-
tonitrile and 50 mM sodium dihydrogen phosphate (17:83;
v/v). The pH was adjusted to 3.1 with phosphoric acid
(Amini and Ahmadiani 2010). The sample volume was
40 ll. All chromatograms were obtained at a conditioned
temperature (40 C), and the flow rate was 1.3 ml/min.
Rivastigmine was used as an internal standard (Amini and
Ahmadiani 2010). The described analytical method is
sensitive for donepezil and also for rivastigmine, and may
be used for both acetylcholinesterase inhibitors. The sam-
ples were analysed by a UV detector, and the maximum
wavelength of donepezil was 210 nm.
Sample Preparation
Extraction was performed with 20 ll of 1 M sodium
hydroxide and 3 ml of 1-butanol/n-hexane (2:98; v/v) to
1 ml plasma or CSF; subsequently, the samples were
intensely shaken for 5 min and centrifuged at
11,0009g and 10 C for 10 min. The entire organic layer
was separated into a new tube, and re-extraction was per-
formed with 100 ll of 0.1 % acetic acid (Amini and
Ahmadiani 2010). The mixture was intensely shaken and
centrifuged. The lower aqueous phase was separated and
directly injected into the HPLC system.
Preparation of Calibration Standards
and Calculation of Assayed Concentrations
Calibration standards were established using blank human
plasma or human CSF supplemented with donepezil in a
range of concentrations (0, 3.125, 6.25, 12.5, 25, 50, and
100 ng/ml; in triplicate); see Fig. 1.
Regression analysis of the relationship between peak
areas and theoretical concentrations of calibration stan-
dards was performed with the least-squares method using
Prism4 (GraphPad Software, USA). Endogenous com-
pounds in the plasma and CSF were efficiently separated
from donepezil by sample preparation and elution for
23 min. The donepezil concentration exhibited a linear
relationship (r2[ 0.9967 in plasma; r2[ 0.9983 in CSF)
Table 1 Steady-state
pharmacokinetic parameters of
donepezil (Noetzli and Eap
2013)
Parameter Donepezil
Daily dose (mg) 5–10, 23a
Bioavailability (%) 100
Protein binding (%) 93
t1/2 (h) 70
b
tmax,ss (h) 4 (IR), 6 (SR)
Cmax,ss (ng/mL) 61 ± 10 (10 mg/day), 129 (CV 29 %) (23 mg/day)
a
AUCmax,ss (ng h/mL) 1128 ± 196 (10 mg/day)
c
CLtot (L/h) 10 ± 2.5
c
Vd (L/kg) 11 ± 2
c
Metabolism Hepatic (CYP2D6, CYP3A4, UGT)
Kinetics Linear
Steady state (days) 14–21
AUCss area under the concentration–time curve at steady state, cap capsule; CLtot total systemic clearance,
Cmax,ss maximum steady-state plasma drug concentration during a dosage interval, CV coefficient of
variation, CYP cytochrome P450, ER extended-release formulation, IR immediate-release formulation, SR
sustained-release formulation, t elimination half-life, tmax,ss time to reach Cmax,ss UGT uridine
50-diphosphoglucuronosyltransferase, Vd apparent volume of distribution
a The new dosage of 23 mg has recently been approved by the US FDA for the treatment of moderate-to-
severe Alzheimer’s disease
b The t of the drug is short, but the duration of action is longer because acetylcholinesterase and
butyrylcholinesterase are inhibited for 8.5 and 3.5 h, respectively, through a pseudoirreversible mechanism
c Mean ± standard deviation or range
164 Neurotox Res (2017) 31:162–168
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between the peak areas and calibration standards in the
range of 3.125–100 ng/ml in the plasma and CSF.
Precision in Plasma and CSF Samples
Intra-day precision was determined by repeating the
measurement of spiked samples ten times with five dif-
ferent concentrations of plasma and CSF (6.25, 12.5, 25,
50, and 100 ng/ml; n = 4) on the same day. Inter-day
precision was determined by calculating the means of four
replicates of samples spiked with donepezil (plasma and
CSF: 6.25, 12.5, 25, 50, and 100 ng/ml) on 3 subsequent
days.
The intra-day and inter-day coefficients of variations
(C.V.) of donepezil are summarised in Table 2.
Accuracy in Plasma and CSF Samples
Donepezil in plasma samples (6.25, 12.5, 25, 50, and
100 ng/ml) was quantified once a day on 10 different days.
The accuracy was 98.4 % (6.25 ng/ml), 98.7 % (12.5 ng/
ml), 98.9 % (25 ng/ml), 99.3 % (50 ng/ml), and 99.7 %
(100 ng/ml), respectively.
Donepezil in CSF samples at the same concentrations
was quantified in the same way. The accuracy was 98.1 %
(6.25 ng/ml), 98.3 % (12.5 ng/ml), 99.0 % (25 ng/ml),
99.0 % (50 ng/ml), and 99.1 % (100 ng/ml), respectively.
Limit of Quantification (LOQ) and Limit
of Detection (LOD) in Plasma and CSF Samples
LOQ was calculated as the lowest concentration of samples
which were measured with a precision of 20 % and a rel-
ative error of ±20 %. The LOD was derived from LOQ
according to the equation LOD = (3.3 9 LOQ)/10.
The donepezil LOQ in plasma samples was 1.56 ng/ml
and the LOD was 0.52 ng/ml. The donepezil LOQ in CSF
samples was 3.13 ng/ml and the LOD was 1.03 ng/ml.
Statistical Analysis
The concentrations of donepezil in human plasma and human
CSF were calculated from the areas under the peaks using the
calibration curve. The calibration curve was calculated by
Prism4 statistical software (Graph Pad Software, USA).
Statistical analysis was performed using software IBM
SPSS Statistics. The mean and SEM (Standard Error of
the Mean) were calculated for plasma and CSF concen-










Fig. 1 Calibration curve of donepezil in human CSF
Table 2 Inter- and intra-day precision in plasma and cerebrospinal fluid samples
Plasma concentration CSF concentration
Added (ng/ml) donepezil C. V. % Mean ± SEM N Added (ng/ml) donepezil C. V. % Mean ± SEM N
Inter-day Inter-day
6.25 3.23 6.2 ± 0.2 10 6.25 4.76 6.3 ± 0.3 10
12.5 3.25 12.3 ± 0.4 10 12.5 4.84 12.4 ± 0.6 10
25 3.13 25.6 ± 0.8 10 25 3.54 25.4 ± 0.9 10
50 2.23 49.4 ± 1.1 10 50 3.82 49.7 ± 1.9 10
100 1.73 98.3 ± 1.7 10 100 3.29 100.3 ± 3.3 10
Intra-day Intra-day
6.25 4.76 6.3 ± 0.3 3 6.25 6.45 6.2 ± 0.4 3
12.5 4.84 12.4 ± 0.6 3 12.5 1.60 12.5 ± 0.2 3
25 4.59 26.1 ± 1.2 3 25 3.50 25.7 ± 0.9 3
50 2.18 50.5 ± 1.1 3 50 2.42 49.5 ± 1.2 3
100 2.02 99.1 ± 2.0 3 100 2.57 101.1 ± 2.6 3
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trations of donepezil. Difference between sampling inter-
vals (12, 24 h) were evaluated via nonparametric Mann–
Whitney U test, and the differences were considered sig-
nificant at a significance level 2a = 0.05.
Results
Sixteen patients regularly taking a standard therapeutic
dose of donepezil (10 mg per day) were recruited into this
clinical study. The patients were randomly divided into two
groups depending on the time of plasma and CSF sam-
pling: 12 or 24 h after donepezil administration. Differ-
ences in plasma and CSF donepezil concentrations were
found between the 12- and 24-h groups, and the concen-
tration changes are summarised in Table 3.
The mean plasma concentration of donepezil was sub-
jectively elevated after 12 h (39.99 ± 5.90 ng/ml) com-
pared with 24-h interval (29.38 ± 1.71 ng/ml), although
this difference was not statistically significant (U = 22.0,
Z = -1.006, p = 0.35). In contrast, elevated CSF con-
centration of donepezil was found after 24 h (7.54 ±
0.55 ng/ml) compared with 12-h interval (5.19 ± 0.83 ng/
ml; results exclude concentrations under LOD), and this
effect was statistically significant (U = 7.5, Z = -2.177,
p = 0.03). No correlation between plasma and CSF con-
centrations of donepezil was found.
Discussion
The profile of donepezil with respect to its absorption,
metabolic pathways, drug–drug interaction, and clearance
is well established (Seltzer 2005). Hence, we focused here
on the long-term 3-month steady-state concentration profile
of donepezil in the plasma and CSF of AD patients, and its
fluctuations between 12 and 24 h post dosing. This study
contributed to broaden our information on plasma and CSF
donepezil concentrations, particularly with respect to
donepezil concentration fluctuation after 12 and 24 h post
morning dosage which was rare and limited until this time
(Tiseo et al. 1998; Darreh-Shori et al. 2006; Jelic and
Darreh-Shori 2010). The plasma concentrations of done-
pezil were 30 ng/ml in patients receiving 5 mg/day and
60 ng/ml in patients receiving 10 mg/day of the drug.
Reports pertaining to the distribution of donepezil in the
CSF are very scarce. However, Darreh-Shori et al. (2006)
showed that the long-term donepezil concentration profile
in the CSF differs from that in the plasma. The CSF
donepezil concentration appears to be approximately ten-
fold lower compared with plasma levels but exhibits a
similar dose-proportional pattern. In addition, there are
indications of the pharmacokinetics of donepezil in the
CSF but not in the plasma (Darreh-Shori et al. 2006). The
donepezil concentration in the CSF has been found to
increase by 50 % between 12 and 24 months of treatment
Table 3 Donepezil concentrations in human plasma and cerebrospinal fluid and cerebrospinal concentration (% of plasma)
Time interval Patient no. Age MMSE Donepezil concentration CSF concentration (% of plasma)
Plasma (ng/ml) CSF (ng/ml)
12 h 1 74 18 47.18 4.20 8.90
2 84 15 17.29 Under LOD –
3 83 23 24.09 2.42 10.04
4 82 17 69.26 4.29 6.19
5 80 18 44.71 5.10 11.40
6 75 11 38.54 5.41 14.03
7 83 19 13.92 Under LOD –
8 62 7 43.10 4.80 11.14
9 85 22 61.38 10.10 16.45
Mean ± SEM 39.99 – 5.90 5.19 – 0.83
24 h 1 79 22 29.47 6.24 21.02
2 73 18 26.93 6.65 24.91
3 79 27 27.16 5.41 19.85
4 88 24 40.30 8.62 21.34
5 78 15 27.14 7.42 27.31
6 71 17 27.34 9.85 35.90
7 72 20 27.33 8.62 31.50
Mean ± SEM 29.38 – 1.71 7.54 – 0.55
166 Neurotox Res (2017) 31:162–168
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in AD patients receiving the same dose at both intervals
(Darreh-shori et al. 2006). This study demonstrated a clear
time dependence of the pharmacokinetics of donepezil
because the CSF concentration at 24 h after the last
administration was approximately one-third higher than
that after 12 h. The low concentration of donepezil in
plasma and a CSF concentration below LOD in two of the
patients were most likely due to noncompliance. The
concentration of donepezil in CSF achieved 11.25 ± 1.18
and 25.97 ± 2.09 % 12 and 24 h post administration,
compared with actual plasma concentrations (n = 7,
mean ± SEM), respectively.
Modern imaging methods showed that the dose of
donepezil 5 and 10 mg inhibited cortical AChE activity by
only 20–40 % in vivo (Kuhl et al. 2000). These findings
suggest that higher doses of donepezil provide greater
inhibition and better clinical effects. A dose of 23 mg of
donepezil per day was shown to be more effective than
lower doses (5 and 10 mg) and was well tolerated (Sabbagh
and Cummings 2011). The pharmacological effects depend
not only on the dose increase but also on the drug formu-
lation (sustained-release tablets with 23 mg vs. immediate-
release tablets with 5 and 10 mg). The higher dosage is
recommended by the Expert Working Group (EWG) for
the treatment of moderate-to-severe AD (monotherapy or
in combination with memantine) (Cummings et al. 2013).
These clinical data support higher dosing of donepezil in
the treatment of AD. In the EU, the maximum recom-
mended dose is 10 mg daily, and in the USA the FDA-
approved dose is 23 mg daily (Doody et al. 2008; Farlow
et al. 2010; Noetzli and Eap 2013).
The other factor that may influence the final donepezil
concentration in the CSF of AD patients is the active efflux
mechanism across the blood–brain barrier (BBB).
According to previously published studies, P-gp (P-glyco-
protein) is an important determinant for the disposition of
donepezil, influencing its efflux from the central compart-
ment to the blood stream (Ishiwata et al. 2007). It should be
noted that BBB P-gp is degraded in the progressive
pathogenesis of AD and hence a higher CSF donepezil
concentration may be found in patients in an advanced
stage of the disease (Hartz et al. 2010).
The limitation of this study is relatively small sample
size due to the difficulty of recruiting patients consenting to
undergo the invasive lumbar puncture procedure. In addi-
tion, the compliance of patients could not be reliably
assessed. Also, we expected to find higher concentrations
of donepezil in plasma and CSF (based on previously
published clinical studies focused on plasma concentration,
and also according to our in vivo preclinical data, Jana
Zdarova Karasova personal unpublished result). On the
other hand, donepezil concentration measured by the
selected method was well detected also in low
concentrations. Despite these limitations, our study is a
original work focused on donepezil concentrations in the
CSF between doses. Further studies with larger numbers of
patients are necessary to verify our results.
Conclusion
This study supported the use of higher doses of donepezil
in the treatment of AD, since its concentration in the CSF is
relatively low and unstable throughout the whole day. The
CSF concentration of donepezil achieved 25.97 ± 2.09 %
of plasma concentration in 24 h and only 11.25 ± 1.18 %
in 12 h compared with actual plasma concentrations
(n = 7, mean ± SEM). Based on CSF data, it is plausible
to predict that donepezil might produce a stronger AChE
inhibition in the brain at 24 h compared with 12 h fol-
lowing the administration. This information may help
physicians individually adjust the time of drug adminis-
tration in the patients according to time course of the dis-
ease symptoms.
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